Synergistic effect of photodynamic therapy and cisplatin: A novel approach for cervical cancer

Journal of Photochemistry and Photobiology B: Biology

Volumn 140, Issue , 2014, Pages 365-373

  De Freitas, Laura Marise ^a   Soares, Christiane Pienna ^a   Fontana, Carla Raquel ^a  

^a SÃO PAULO STATE UNIVERSITY UNESP   (Brazil)

Author keywords

Cervical cancer; Cisplatin; Combined therapy; Photodynamic therapy

Indexed keywords

CISPLATIN; METHYLENE BLUE; PHOTOGEM; PHOTOSENSITIZING AGENT; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL VIABILITY; CERVICAL CANCER CELL LINE; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFICACY; DRUG POTENTIATION; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; LIGHT; LIGHT EMITTING DIODE; MONOTHERAPY; MTT ASSAY; PHOTODYNAMIC THERAPY; UTERINE CERVIX CANCER; CELL SURVIVAL; DRUG EFFECTS; HUMAN PAPILLOMAVIRUS TYPE 16; PHOTOCHEMOTHERAPY; PHYSIOLOGY; RADIATION RESPONSE; TUMOR CELL LINE; UTERINE CERVICAL NEOPLASMS; VIROLOGY;

CELL LINE, TUMOR; CELL SURVIVAL; CISPLATIN; DRUG SYNERGISM; FEMALE; HUMAN PAPILLOMAVIRUS 16; HUMANS; PHOTOCHEMOTHERAPY; PHOTOSENSITIZING AGENTS; UTERINE CERVICAL NEOPLASMS;

EID: 84907242698     PISSN: 10111344     EISSN: 18732682     Source Type: Journal    
DOI: 10.1016/j.jphotobiol.2014.08.021     Document Type: Article

References (28)

1. S. de Sanjosé, B. Serrano, X. Castellsagué, M. Brotons, J. Muñoz, L. Bruni, F.X. Bosch, Human papillomavirus (HPV) and related cancers in the Global Alliance for Vaccines and Immunization (GAVI) countries. A WHO/ICO HPV Information Centre Report, Vaccine, 20;30 Suppl 4:D1-83, 2012, doi: 10.1016/S0264-410X(12)01435-1.
2. E.L. Franco, E. Duarte-Franco, and A. Ferenczy Cervical cancer: epidemiology, prevention and the role of human papillomavirus infection Can. Med. Assoc. 164 7 2001 1017 1025
3. R. Roden, and T.-C. Wu How will HPV vaccines affect cervical cancer? Nat. Rev. Cancer 6 10 2006 753 763 10.1038/nrc1973
4. A.G. Linard, F.A. Dantas e silva, and R.M. Silva Mulheres submetidas a tratamento para câncer de colo uterino - percepção de como enfrentam a realidade∗ Women submitted to cervix uteri cancer treatment: how they cope with reality Rev. Bras. Canc. 48 4 2002 493 498
5. S.C. Dowdy, C.H. Boardman, T.O. Wilson, K.C. Podratz, L.C. Hartmann, and H.J. Long Multimodal therapy including neoadjuvant methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) for stage IIB to IV cervical cancer Am. J. Obstet. Gynecol. 186 6 2002 1167 1173 10.1067/mob.2002.123820
6. N.M. Wolschick, M.E.L. Consolaro, L.E. Suzuki, and C.G. Boer Câncer do colo do útero: tecnologias emergentes no diagnóstico, tratamento e prevenção da doença/cervical uterine cancer: emerging technologies on the diagnosis, treatment and disease prevention Rev. Bras. Anal. Clin. 39 2 2007 123 129
7. K.B. Meyer, and N.E. Madias Cisplatin nephrotoxicity Miner. Electrolyte Metab. 20 1994 201 213
8. M. Crul, R.C.A. van Waardenburg, J.H. Beijnen, and J.H.M. Schellens DNA-based drug interactions of cisplatin Cancer Treat. Rev. 28 6 2002 291 303 10.1016/S0305-7372(02)00093-2
9. T.J. Dougherty, and S.L. Marcus Feature articles photodynamic therapy Eur. J. Cancer 1992 1734 1742
10. D.E. Dolmans, D. Fukumura, and R.K. Jain Photodynamic therapy for cancer Nat. Rev. Cancer 3 5 2003 375 380 10.1038/nrc1071
11. S.B. Brown, E.A. Brown, and I. Walker Review the present and future role of photodynamic therapy in cancer treatment Lancet Oncol. 5 2004 497 508 10.1016/S1470-2045(04)01529-3
12. G. Canti, A. Nicolin, R. Cubeddu, P. Taroni, G. Bandieramonte, and G. Valentini Antitumor efficacy of the combination of photodynamic therapy and chemotherapy in murine tumors Cancer Lett. 125 1-2 1998 39 44 10.1016/S0304-3835(97)00502-8
13. D.K. Kelleher, J. Bastian, O. Thews, and P. Vaupel Enhanced effects of aminolaevulinic acid-based photodynamic therapy through local hyperthermia in rat tumours Br. J. Cancer 89 2003 405 441 10.1038/sj.bjc.6601036
14. F. Denizot, and R. Lang Rapid colorimetric assay for cell growth and survival modifications to the tetrazolium dye procedure giving improved sensitivity and reliability J. Immunol. Methods 89 1986 271 277 10.1016/0022-1759(86)90368-6
15. S.M. Sharkey, B.C. Wilson, R. Moorehead, and G. Singh Mitochondria! Alterations in photodynamic therapy-resistant cells Cancer Res. 53 1993 4994 4999
16. A. Leunig, F. Staub, J. Peters, A. Heimann, C. Csapo, O. Kempski, and A.E. Goetz Relation of early photofrin uptake to photodynamically induced phototoxicity and changes of cell volume in different cell lines Eur. J. Cancer 30A 1 1994 78 83
17. Y. Chen, W. Zheng, Y. Li, J. Zhong, J. Ji, and P. Shen Apoptosis induced by methylene-blue-mediated photodynamic therapy in melanomas and the involvement of mitochondrial dysfunction revealed by proteomics Cancer Sci. 99 10 2008 2019 2027 10.1111/j.1349-7006.2008.00910.x
18. A. Blázquez-Castro, J.C. Stockert, F. Sanz-Rodríguez, A. Zamarrón, and A. Juarranza Differential photodynamic response of cultured cells to methylene blue and toluidine blue: role of dark redox processes Photochem. Photobiol. Sci. 8 3 2009 371 376 10.1039/b818585a
19. I. Postiglione, A. Chiaviello, and G. Palumbo Enhancing photodynamic therapy efficacy by combination therapy: dated, current and oncoming strategies Cancers 3 2011 2597 2629 10.3390/cancers3022597
20. A.E. O'Connor, W.M. Gallagher, and A.T. Byrne Porphyrin and nonporphyrin photosensitizers in oncology: preclinical and clinical advances in photodynamic therapy Photochem. Photobiol. 85 2009 1053 1074 10.1111/j.1751-1097.2009.00585.x
21. M. Kadaja, H. Isok-Paas, T. Laos, E. Ustav, and M. Ustav Mechanism of genomic instability in cells infected with the high-risk human papillomaviruses PLoS Pathog. 5 4 2009 1 16 10.1371/journal.ppat.1000397
22. H. Schuldes, S. Bade, J. Knobloch, and D. Jonas Loss of in vitro cytotoxicity of cisplatin after storage as stock solution in cell culture medium at various temperatures Cancer 79 9 1997 1723 1728 10.1002/(SICI)1097-0142(19970501)79:9<1723::AID-CNCR13>3.0.CO;2-#
23. C.J. Kao, G.T. Wurz, A.M. Monjazeb, D.P. Vang, T.B. Cadman, S.M. Griffey, M. Wolf, and M.W. Degregorio Antitumor effects of cisplatin combined with tecemotide immunotherapy in a human MUC1 transgenic lung cancer mouse model Cancer Immunol. Res. 2 6 2014 581 589 10.1158/2326-6066.CIR-13-0205
24. G. Hermann, P. Heffeter, T. Falta, W. Berger, S. Hanna, and G. Koellensperger In vitro studies on cisplatin focusing on kinetic aspects of intracellular chemistry by LC-ICP-MS Metallomics 5 2013 636 647 10.1039/c3mt20251h
25. C.P. Saris, P.J.M. van de Vaart, R.C. Rietbroek, and F.A. Bloramaert In vitro formation of DNA adducts by cisplatin, lobaplatin and oxaliplatin in calf thymus DNA in solution and in cultured human cells Carcinogenesis 17 12 1996 2763 2769
26. A.M.J. Fichtinger-Schepman, S.D. Van der Yelde-Visser, H.C.M. Van Dijk-Knijnenburg, A.T. van Oosterom, R.A. Baan, and F. Berends Kinetics of the formation and removal of cisplatin-DNA adducts in blood cells and tumor tissue of cancer patients receiving chemotherapy: comparison with in vitro adduct formation Cancer Res. 50 1990 7887 7894
27. D.P. Gately, and S.B. Howell Cellular accumulation of the anticancer agent cisplatin: a review Br. J. Cancer 67 6 1993 1171 1176
28. E. Shaili Platinum anticancer drugs and photochemotherapeutic agents: recent advances and future developments Sci. Prog. 97 2014 20 40 10.3184/003685014X13904811808460